# A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667

> **NCT04097938** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 52 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GLPG3667 oral suspension
- **DRUG:** Placebos
- **DRUG:** GLPG3667 capsules

## Key facts

- **NCT ID:** NCT04097938
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-18
- **Primary completion:** 2020-03-04
- **Final completion:** 2020-07-06
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04097938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04097938, "A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04097938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*